Genome Medical
South San Francisco, US · Founded 2016 · 18 known investors
Find your way into Genome Medical
Each arrow is one introduction. Sign up to fill in the first one.
Ask Monika Roots to introduce you to Mark Sylvester
You →Monika · together at The Emily Program →Mark
Ask Jamie Chen to introduce you to Durand Van Arnem
You →Jamie · together at NucleusHealth →Durand
Ask Sam Okafor to introduce you to Andrew Warner
You →Sam · together at Genome Medical →Andrew
- Monica Zarb70 people can intro you
Sign up to find every way you can get introduced to Genome Medical
- Your email: who you already know at Genome Medical, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Genome Medical team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Genome Medical provides telehealth-enabled genetic services, including genetic counseling, genetic testing, and clinical trial matching, with a focus on individuals with rare conditions. It partners with hospitals and health systems, life sciences organizations, and genetic testing labs to expand patient access and improve care.
Also known as Genome Medical
Founders & leadership
Genome Medical was founded in 2016 by Lisa Alderson and Randal Scott.





Board
Investors · 18
How we know: av.vc · Not right? Tell us
How we know: Avestria Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Canaan Partners's portfolio page · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Dreamers VC's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Echo Health Ventures's portfolio page · board seat on SEC Form D · Not right? Tell us
How we know: GV (Google Ventures)'s portfolio page · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Illumina Ventures's portfolio page · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Kaiser Permanente Ventures's portfolio page · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Pearl Abyss Capital's portfolio page · Not right? Tell us
How we know: Premier Partners's portfolio page · Not right? Tell us
How we know: Samsung Catalyst Fund's portfolio page · press coverage · Not right? Tell us
How we know: Walden Catalyst's portfolio page · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$90M disclosed across 3 rounds · 2018–2024
▶$75.3MraisedSep 2024 · 14 investors · Other Health CareRule 506(b)
- Jill DaviesExecutive Officer, Director
- Shaun RodriguezDirector
- Elizabeth MorenoExecutive Officer
- Alex ParkerDirector
- Mark SylvesterExecutive Officer
- Russell GlassDirector
- Offering amount
- $75.3M
- Amount sold
- $75.3M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.4MraisedJul 2020 · 21 investors · Other Health CareRule 506(b)
- Jessica ZeaskeDirector
- Randal W. ScottDirector
- Minh MerchantExecutive Officer
- Stephen BlochDirector
- Kristin AshcraftExecutive Officer
- Lisa J. AldersonExecutive Officer, Director
- Nicholas NaclerioDirector
- Tim HoweDirector
- Robert C. GreenDirector
- Offering amount
- $15M
- Amount sold
- $14.4M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$223.2KraisedAug 2018 · 1 investors · Other TechnologyRule 506(b)
- Stephen BlochDirector
- Iana DimkovaDirector
- Nicholas NaclerioDirector
- Lisa AldersonExecutive Officer, Director
- Randal ScottDirector
- Tim HoweDirector
- Robert GreenDirector
- Offering amount
- $223.2K
- Amount sold
- $223.2K
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Genome Medical is a telehealth-enabled genetic services company founded in 2016 that connects patients and their providers with genetic counselors, medical geneticists and physicians. Patients can schedule appointments without a provider referral and typically meet a board-certified genetic counselor within one week, via a 30-60 minute phone consultation. Clinicians review personal and family medical history, order genetic testing when medically appropriate (often using a mailed saliva collection kit, with most results returned in two to four weeks), and provide a results consultation plus a written summary the patient can share with their care team.
The company positions itself around rare disease care, describing a market in which patients often experience long diagnostic journeys and multiple misdiagnoses while new clinical trials and gene therapies emerge for previously untreatable conditions. Its service lines include genetic counseling, genetic test ordering, sponsored testing programs, patient recruitment for trials based on genetic eligibility criteria, and peer-to-peer genetics support for other clinicians. Patients may opt in to be notified about relevant clinical trial opportunities. Clinical coverage spans rare disease, cardiology, neurology, pediatrics and oncology, with named clinical leads for cancer, cardiovascular and pediatric, and neurology and adult genetic services.
Genome Medical describes itself as clinician-led and led by genetic counselors, with a care delivery technology platform supporting its services. GeneMatters is identified on the company's site as a Genome Medical company, with former GeneMatters clients and patients directed to log in through Genome Medical's website.
Founding story
The company was founded in 2016 on the premise that expert genetic guidance should be accessible to all, and is described as led by genetic counselors seeking to combine clinical genetics expertise with tech-enabled care delivery to close access gaps, particularly for patients with rare conditions.
Business model
Genome Medical sells genetic services both directly to patients and through organizational partners. Individuals can self-schedule telehealth genetic counseling; the company is an in-network provider with most commercial health insurance plans and bills insurance where applicable, while also offering self-pay and a financial assistance program. In parallel, it contracts with hospitals and health systems, life sciences and biopharmaceutical organizations, and genetic testing laboratories, delivering counseling, test ordering, sponsored testing programs, trial patient recruitment and peer-to-peer clinician support on their behalf. The company states it is lab- and test-agnostic and partners with most major genetic testing labs.
Revenue comes from patient consultations and partner contracts. A genetic counseling visit costs up to $250 depending on whether insurance or self-pay is used, with genetic testing billed separately and not included in the counseling fee. The company bills commercial insurers where in-network, using CPT codes 96041 and S0265; it states it does not accept government-affiliated plans such as Medicaid, Medicare or Tricare as primary or secondary insurance. Partner-side revenue derives from services provided to hospitals and health systems, life sciences organizations and genetic testing laboratories.
Traction
Reported metrics include over 250,000 total genetic counseling consults delivered, a 96% patient satisfaction rating, 148 million-plus covered lives, a team of more than 35 clinicians licensed across all 50 states, and genetic counselors with an average of over 10 years of experience. The company marked ten years of operation in a 2025-2026 anniversary campaign.
Latest developments
Recent company communications include a ten-year anniversary campaign on making genetics care accessible, publication of a white paper on inherited retinal diseases ("Voice of the Patient"), and new patient insights on rare epilepsy care. The site also notes the integration of GeneMatters as a Genome Medical company, including consolidated patient and client login.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
The company describes itself as the leading provider of telehealth-enabled genetic services, differentiating on clinical depth in rare disease genetics. Reported scale includes more than 250,000 genetic counseling consults delivered, more than 35 clinicians, 148 million-plus covered lives and a 96% patient satisfaction rating.
Stated differentiators include being clinician- and genetic counselor-led; a multidisciplinary clinical team of genetic counselors, medical geneticists and primary care physicians averaging more than 10 years of experience; lab- and test-agnostic service delivery with most major genetic testing labs; appointment availability within one week without a referral; in-network status with most commercial insurance plans; nationwide coverage in all 50 states; and integration of clinical trial matching with counseling and testing.
Technology
The company delivers care through a telehealth and digital health technology platform that supports appointment scheduling, a patient portal for uploading prior genetic test results, phone-based consultations, test ordering workflows and results delivery. The platform enables provision of genetic services across all 50 states and supports identification of patients meeting genetic eligibility criteria for clinical trials.
Go-to-market
Genome Medical markets directly to consumers through self-scheduled, referral-free telehealth appointments and educational resources (blog articles, case studies, white papers, research and events), while pursuing B2B partnerships with hospitals and health systems, life sciences organizations and genetic testing labs. Published resources include a white paper on inherited retinal diseases and patient insights work on rare epilepsy care.
Two groups: individuals and families concerned about inherited or rare genetic conditions, including those with a known family mutation or existing test results, and who can self-refer; and institutional partners — hospitals and health systems, biopharmaceutical and life sciences organizations running trials and sponsored testing programs, and genetic testing laboratories seeking to add genetic services to their testing programs.
Geography
Genome Medical provides telehealth genetic services in all 50 U.S. states through its platform. Its rare disease framing references a global patient population of more than 300 million people, but service delivery described on its site is United States-based.
History
Founded in 2016, Genome Medical built a telehealth genetic services business led by genetic counselors. GeneMatters, another genetic counseling services provider, became a Genome Medical company, with GeneMatters clients and patients transitioned to Genome Medical's website and login. The company publicly celebrated ten years of operations, and its current leadership team is headed by CEO Jill Davies alongside a chief financial officer, chief clinical officer, vice presidents of product, strategy, business development and engineering, and clinical directors for cancer, cardiovascular and pediatric, and neurology and adult genetic services.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
4 people who came through Genome Medical went on to found or lead other companies.
Related companies · 5
Companies working in the same space as Genome Medical.
Timeline · 3
launches, deals, and filingsGenome Medical's website states that GeneMatters is now a Genome Medical company, with existing GeneMatters clients and patients directed to access their accounts through the Genome Medical site.
The company publicized a campaign celebrating 10 years of making genetics care accessible, and published a related news article.
Genome Medical published a 'Voice of the Patient' white paper on inherited retinal diseases, alongside new patient insights on rare epilepsy care.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 8
primary sources listed
- Genomegenomemedical.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Genome Medical do?
- Genome Medical is a telehealth provider of genetic counseling, test ordering and clinical trial matching, focused on rare disease.
- Who founded Genome Medical?
- Genome Medical was founded by Lisa Alderson, Randal Scott in 2016.
- Who are Genome Medical's investors?
- Genome Medical's investors include Alumni Ventures, Avestria Ventures, Canaan Partners, Dreamers VC, Echo Health Ventures, GV (Google Ventures), Illumina Ventures, Kaiser Permanente Ventures and 10 more.
- How much funding has Genome Medical raised?
- Genome Medical has disclosed $90M raised across 3 rounds.
- Where is Genome Medical headquartered?
- Genome Medical is headquartered in South San Francisco, US.
















